Lai Yancheng, Lu Xiaole, Liao Yankai, Ouyang Pei, Wang Hai, Zhang Xian, Huang Guanglong, Qi Songtao, Li Yaomin
Department of Neurosurgery, Institute of Brain Disease, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515, China.
Laboratory for Precision Neurosurgery, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515, China.
Genes Dis. 2023 Jul 19;11(2):874-889. doi: 10.1016/j.gendis.2023.05.025. eCollection 2024 Mar.
Glioblastoma (GBM) is the most common intrinsic and aggressive primary brain tumor in adults, with a median survival of approximately 15 months. GBM heterogeneity is considered responsible for the treatment resistance and unfavorable prognosis. Proneural-mesenchymal transition (PMT) represents GBM malignant progression and recurrence, which might be a breakthrough to understand GBM heterogeneity and overcome treatment resistance. PMT is a complicated process influenced by crosstalk between GBM and tumor microenvironment, depending on intricate ligand-receptor interactions. In this review, we summarize the autocrine and paracrine pathways in the GBM microenvironment and related ligand-receptor interactions inducing PMT. We also discuss the current therapies targeting the PMT-related autocrine and paracrine pathways. Together, this review offers a comprehensive understanding of the failure of GBM-targeted therapy and ideas for future tendencies of GBM treatment.
胶质母细胞瘤（GBM）是成人中最常见的原发性脑内侵袭性肿瘤，中位生存期约为15个月。GBM的异质性被认为是治疗耐药和预后不良的原因。神经前体细胞向间充质细胞转变（PMT）代表了GBM的恶性进展和复发，这可能是理解GBM异质性和克服治疗耐药的一个突破。PMT是一个复杂的过程，受GBM与肿瘤微环境之间的相互作用影响，依赖于复杂的配体-受体相互作用。在这篇综述中，我们总结了GBM微环境中的自分泌和旁分泌途径以及诱导PMT的相关配体-受体相互作用。我们还讨论了目前针对与PMT相关的自分泌和旁分泌途径的疗法。总之，这篇综述全面阐述了GBM靶向治疗失败的原因，并为GBM治疗的未来趋势提供了思路。
Zotero 插件